Summary
Eli Lilly has joined a number of pharmaceutical companies pausing or dropping investments in the UK following a fallout with the government over drug pricing.
Gateway Labs, a London-based hub that provides support for biotech startups established last October as part of Lillys planned 279m inve…
Source: The Observer
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
